Infectious disease
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
Biopharma companies who have COVID-19 vaccines in development, have astonished skeptics by the speed with which they have developed vaccines.. But now comes an even more daunting challenge—scaling up manufacturing and distribution.
Nucleic-acid-based assays are the gold standard for detecting the presence of the SARS-CoV-2 virus, but they eventually will be replaced with simpler and more advanced techniques, such as CRISPR-Cas, LAMP, and other faster and less-expensive methods.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
What do you think is how much time is required for vaccine development? In a pandemic, the timeline is less than normal. Want to know why? Read the article and find.
Children, who have not been widely tested in clinical trials for the vaccine, are typically less severely affected and are much further down the priority list for receiving the vaccines. But the vaccine has not been tested at all in younger children.
Yesterday, the United Kingdom’s MHRA granted temporary authorization for emergency use to Pfizer and BioNTech for their COVID-19 mRNA vaccine. It didn’t take long for the decision to generate criticism and questions.
the robustness and independence of FDA review – even under an EUA – is an important factor in encouraging a skeptical public to accept COVID-19 vaccinations.
The U.S. Food and Drug Administration has given Emergency Use Authorization (EUA) to a COVID-19 test developed by Roche that measures antibodies within the blood.
Auris Medical rose by as much as 480% yesterday after it announced lab test results, which appeared to show that its nasal spray could potentially protect users against COVID-19.
PRESS RELEASES